Kent Heberer

Kent Heberer

Auto-generated profile, based on publicly available information

Kent Heberer

VA Palo Alto Cooperative Studies Coordinating Center

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Gait & Posture
Verified
Journal Article
Closed access
KHKent Heberer
Kent Heberer
EFEileen Fowler
Eileen Fowler
LSLoretta Staudt
Loretta Staudt
SSSusan Sienko
Susan Sienko
CBCathleen E. Buckon
Cathleen E. Buckon
MSMichael D. Sussman
Michael D. Sussman

9 December 2022 in Gait & Posture
Verified
Journal Article
Closed access
SSSusan Sienko
Susan Sienko
CBCathleen Buckon
Cathleen Buckon
ABAnita Bagley
Anita Bagley
EFEileen Fowler
Eileen Fowler
KHKent Heberer
Kent Heberer
MSMichael Sussman
Michael Sussman

25 April 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SCSteven Cogill
Steven Cogill
SNShriram Nallamshetty
Shriram Nallamshetty
NFNatalie Fullenkamp
Natalie Fullenkamp
KHKent Heberer
Kent Heberer
JLJulie A Lynch
Julie A Lynch
JLJennifer S. Lee
Jennifer S. Lee
The Omicron SARS-CoV-2 variant continues to strain healthcare systems. Developing tools that facilitate the identification of patients at highest risk of adverse outcomes is a priority. The study objectives are to develop population-scale predictive models that: 1) identify predictors of adverse outcomes with Omicron surge SARS-CoV-2 infections, and 2) predict the impact of prioritized vaccination of high-risk groups for said outcome. We prepared a retrospective longitudinal observational study of a national cohort of 172,814 patients in the U.S. Veteran Health Administration who tested positive for SARS-CoV-2 from January 15 to August 15, 2022. We utilized sociodemographic characteristics, comorbidities, and vaccination status, at time of testing positive for SARS-CoV-2 to predict hospitalization, escalation of care (high-flow oxygen, mechanical ventilation, vasopressor use, dialysis, or extracorporeal membrane oxygenation), and death within 30 days. Machine learning models demonstrated that advanced age, high comorbidity burden, lower body mass index, unvaccinated status, and oral anticoagulant use were the important predictors of hospitalization and escalation of care. Similar factors predicted death. However, anticoagulant use did not predict mortality risk. The all-cause death model showed the highest discrimination (Area Under the Curve (AUC) = 0.903, 95% Confidence Interval (CI): 0.895, 0.911) followed by hospitalization (AUC = 0.822, CI: 0.818, 0.826), then escalation of care (AUC = 0.793, CI: 0.784, 0.805). Assuming a vaccine efficacy range of 70.8 to 78.7%, our simulations projected that targeted prevention in the highest risk group may have reduced 30-day hospitalization and death in more than 2 of 5 unvaccinated patients.

21 February 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HSHannah M. Seagle
Hannah M. Seagle
AAAlexis T. Akerele
Alexis T. Akerele
JDJoseph A. DeCorte
Joseph A. DeCorte
JHJacklyn N. Hellwege
Jacklyn N. Hellwege
JBJoseph H. Breeyear
Joseph H. Breeyear
MVMarijana Vujkovic
Marijana Vujkovic
Summary: Identification of drug-repurposing targets with genetic and biological support is an economically and temporally efficient strategy for improving treatment of diseases. We employed a cross-disciplinary approach to identify potential treatments for metabolic dysfunction associated steatotic liver disease (MASLD) using humans as a model organism. We identified 212 putative causal genes associated with MASLD using data from a large multi-ancestry genetic association study, of which 158 (74.5%) are novel. From this set we identified 57 genes that encode for druggable protein targets, and where the effects of increasing genetically predicted gene expression on MASLD risk align with the function of that drug on the protein target. These potential targets were then evaluated for evidence of efficacy using Mendelian randomization, pathway analysis, and protein structural modeling. Using these approaches, we present compelling evidence to suggest activation of FADS1 by icosopent ethyl as well as S1PR2 by fingolimod could be promising therapeutic strategies for MASLD.

9 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
SCSteven Cogill
Steven Cogill
SNShriram Nallamshetty
Shriram Nallamshetty
NFNatalie Fullenkamp
Natalie Fullenkamp
KHKent Heberer
Kent Heberer
JLJulie A Lynch
Julie A Lynch
JLJennifer S Lee
Jennifer S Lee
The Omicron SARS-CoV-2 variant continues to strain healthcare systems. Developing tools that facilitate the identification of patients at highest risk of adverse outcomes is a priority. The study objectives are to develop population-scale predictive models that: 1) identify predictors of adverse outcomes with Omicron surge SARS-CoV-2 infections, and 2) predict the impact of prioritized vaccination of high-risk groups for said outcome. We prepared a retrospective longitudinal observational study of a national cohort of 192,984 patients in the U.S. Veteran Health Administration who tested positive for SARS-CoV-2 from January 15 to August 15, 2022. We utilized sociodemographic characteristics, comorbidities, vaccination status, and prior COVID-19 infections, at time of testing positive for SARS-CoV-2 to predict hospitalization, escalation of care (high-flow oxygen, mechanical ventilation, vasopressor use, dialysis, or extracorporeal membrane oxygenation), and death within 30 days. Machine learning models demonstrated that advanced age, high comorbidity burden, lower body mass index, unvaccinated status, prior SARS-CoV-2 infection, and oral anticoagulant use were the important predictors of hospitalization and escalation of care. Similar factors predicted death. However, prior SARS-CoV-2 infection was associated with lower 30-day mortality, and anticoagulant use did not predict mortality risk. The all-cause death model showed the highest discrimination (Area Under the Curve (AUC) = 0.895, 95% Confidence Interval (CI): 0.885, 0.906) followed by hospitalization (AUC = 0.829, CI: 0.825, 0.834), then escalation of care (AUC=0.805, CI: 0.795, 0.814). Assuming a vaccine efficacy range of 70.8 to 78.7%, our simulations projected that targeted prevention in the highest risk group may have reduced 30-day hospitalization, care escalation, and death in more than 2 of 5 unvaccinated patients.

18 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KHKent Heberer
Kent Heberer
ABAdam Bress
Adam Bress
SCSteven Cogill
Steven Cogill
AMAna I. Maldonado
Ana I. Maldonado
SKSun H. Kim
Sun H. Kim
JLJennifer S. Lee
Jennifer S. Lee
Importance: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are among the safest and most effective medications for diabetes and weight loss and are currently used by millions of individuals worldwide. While their cardiometabolic benefits are well established, emerging observational reports have raised concerns about a potential association between GLP-1 RA use and new-onset non-arteritic anterior ischemic optic neuropathy (NAION). Objective: To emulate a target trial evaluating the risk of NAION associated with initiation of semaglutide, a GLP-1RA, compared with a sodium-glucose cotransporter-2 inhibitor (SGLT2i) as second-line therapy for type 2 diabetes in a nationwide cohort of U.S. Veterans. Design: Active-comparator, new-user, target trial emulation. Marginal cause-specific hazard ratios (HRs) were estimated using overlap weighting to account for confounding. Data analysis was conducted from July 2025 to September 2025. Setting: The Veterans Health Administration (VHA) nationwide health care system between March 1, 2018 and March 1, 2025. Participants: U.S. Veterans with a diagnosis of type 2 diabetes who were current metformin users and had no prior exposure to GLP-1RAs or SGLT2is. Exposure: Initiation of semaglutide or any SGLT2i. Main Outcome and Measure: Incident NAION, identified using ICD-10 and SNOMED diagnosis codes. Results: A total of 102,361 Veterans met inclusion criteria, including 11,478 new initiators of semaglutide and 90,883 new initiators of an SGLT2i. Baseline characteristics were well balanced between treatment groups after overlap weighting (mean [SD] age, 60.1 [11.7] years; BMI, 37.8 [6.7] kg/m 2 ; hemoglobin A1c, 7.0% [1.4]; 85.5% male; 61.9% non-Hispanic White; 20.7% Black; 8.1% Hispanic). Over a median follow-up of 2.1 years, 153 total incident NAION events occurred. The incidence rate of NAION was 123 per 100,000 person-years among semaglutide initiators and 67 per 100,000 person-years among SGLT2i initiators. Patients who initiated semaglutide had a 2.33-fold higher risk than patients who initiated SGLT2i (HR, 2.33; 95% CI, 1.54–3.54; P<.001). Conclusions and Relevance: In this nationwide cohort of U.S. Veterans with type 2 diabetes, patients who initiated semaglutide had over a 2-fold increased risk of NAION compared to patients who initiated SGLT2i.